ScienceGate
Advanced Search
Author Search
Journal Finder
Blog
Sign in / Sign up
ScienceGate
Search
Author Search
Journal Finder
Blog
Sign in / Sign up
Proton vs. photon radiotherapy for MR-guided dose escalation of intraprostatic lesions
Acta Oncologica
◽
10.1080/0284186x.2021.1947523
◽
2021
◽
pp. 1-8
Author(s):
Maryam Moteabbed
◽
Mukesh Harisinghani
◽
Harald Paganetti
◽
Alexei Trofimov
◽
Hsiao-Ming Lu
◽
...
Keyword(s):
Dose Escalation
◽
Photon Radiotherapy
Download Full-text
Related Documents
Cited By
References
326 The practice of 2 hour observation following dose escalation of beta-blocker therapy is not necessary
European Journal of Heart Failure Supplements
◽
10.1016/s1567-4215(05)80211-5
◽
2005
◽
Vol 4
(1)
◽
pp. 76-76
Keyword(s):
Dose Escalation
◽
Beta Blocker
◽
Blocker Therapy
◽
Beta Blocker Therapy
Download Full-text
Palliative Care Pearls: Opioid Dose Escalation in the Treatment of End-of-Life Pain
PsycEXTRA Dataset
◽
10.1037/e507242006-006
◽
2003
◽
Author(s):
Judith A. Kitzes
◽
Keyword(s):
Palliative Care
◽
End Of Life
◽
Dose Escalation
◽
Opioid Dose
Download Full-text
DOSE ESCALATION OF BIOLOGICS IN CROHN'S DISEASE: CRITICAL REVIEW OF OBSERVATIONAL STUDIES
10.26226/morressier.57c5383cd462b80296c9b2f3
◽
2016
◽
Author(s):
Xin Ying Lee
Keyword(s):
Crohn’S Disease
◽
Crohn's Disease
◽
Dose Escalation
◽
Critical Review
◽
Observational Studies
Download Full-text
Use of Two Technologies, Singulex Single Molecule Counting (SMC)TMand Meso Scale Discovery&[reg](MSD) Technology for Drug Levels Determination of an Antibody Therapeutic, MK-A, in Human Serum in a Dose Escalation Study
10.26226/morressier.57d6b2bbd462b8028d88cc5b
◽
2016
◽
Author(s):
Phyllis Conliffe
Keyword(s):
Human Serum
◽
Single Molecule
◽
Dose Escalation
◽
Meso Scale Discovery
◽
Dose Escalation Study
◽
Drug Levels
◽
Meso Scale
Download Full-text
Phase 1, First in Human, Open-Label, Dose-Escalation Study of 609A in China
Case Medical Research
◽
10.31525/ct1-nct03998345
◽
2019
◽
Author(s):
Keyword(s):
Dose Escalation
◽
Phase 1
◽
Open Label
◽
Dose Escalation Study
◽
Label Dose
Download Full-text
Dose-escalation Study of Oral Administration of LP-108 in Patients With Relapsed or Refractory Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML)
Case Medical Research
◽
10.31525/ct1-nct04139434
◽
2019
◽
Author(s):
Keyword(s):
Acute Myeloid Leukemia
◽
Oral Administration
◽
Dose Escalation
◽
Myelodysplastic Syndromes
◽
Myeloid Leukemia
◽
Chronic Myelomonocytic Leukemia
◽
Dose Escalation Study
◽
Myelomonocytic Leukemia
◽
Acute Myeloid
Download Full-text
An Open Label Dose Escalation Trial of CA-4948 in Patients With Acute Myelogenous Leukemia or Myelodysplastic Syndrome
Case Medical Research
◽
10.31525/ct1-nct04278768
◽
2020
◽
Author(s):
Keyword(s):
Myelodysplastic Syndrome
◽
Dose Escalation
◽
Acute Myelogenous Leukemia
◽
Myelogenous Leukemia
◽
Open Label
◽
Label Dose
◽
Acute Myelogenous
Download Full-text
Faculty Opinions recommendation of Phase I dose escalation and pharmacokinetic study of enzastaurin, an oral protein kinase C beta inhibitor, in patients with advanced cancer.
Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature
◽
10.3410/f.1043078.492991
◽
2006
◽
Author(s):
Jeffrey Evans
Keyword(s):
Protein Kinase C
◽
Protein Kinase
◽
Phase I
◽
Advanced Cancer
◽
Pharmacokinetic Study
◽
Dose Escalation
◽
Kinase C
◽
Protein Kinase C Beta
Download Full-text
Faculty Opinions recommendation of Local application of recombinant human fibroblast growth factor-2 on bone repair: a dose-escalation prospective trial on patients with osteotomy.
Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature
◽
10.3410/f.1083008.535984
◽
2007
◽
Author(s):
Per Aspenberg
Keyword(s):
Growth Factor
◽
Fibroblast Growth Factor
◽
Dose Escalation
◽
Human Fibroblast
◽
Bone Repair
◽
Prospective Trial
◽
Local Application
◽
Fibroblast Growth Factor 2
◽
Fibroblast Growth
Download Full-text
Faculty Opinions recommendation of Local delivery of a recombinant adenoassociated vector containing a tumour necrosis factor alpha antagonist gene in inflammatory arthritis: a phase 1 dose-escalation safety and tolerability study.
Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature
◽
10.3410/f.1162910.623534
◽
2009
◽
Author(s):
Ulf Müller-Ladner
Keyword(s):
Tumour Necrosis Factor
◽
Dose Escalation
◽
Inflammatory Arthritis
◽
Tumour Necrosis
◽
Phase 1
◽
Tumour Necrosis Factor Alpha
◽
Necrosis Factor Alpha
◽
Factor Alpha
◽
Alpha Antagonist
◽
Necrosis Factor
Download Full-text
Sign in / Sign up
Close
Export Citation Format
Close
Share Document
Close